Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 2
2021 1
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.
Malik ME, Butt JH, Strange JE, Falkentoft AC, Jensen J, Andersson C, Zahir D, Fosbøl E, Petrie MC, Sattar N, McMurray JJV, Køber L, Schou M. Malik ME, et al. Lancet Healthy Longev. 2023 Oct;4(10):e552-e560. doi: 10.1016/S2666-7568(23)00164-2. Epub 2023 Sep 18. Lancet Healthy Longev. 2023. PMID: 37734395 Free article.
Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021.
Malik ME, Falkentoft AC, Jensen J, Zahir D, Parveen S, Alhakak A, Andersson C, Petrie MC, Sattar N, McMurray JJV, Køber L, Schou M. Malik ME, et al. Lancet Reg Health Eur. 2023 Mar 17;29:100617. doi: 10.1016/j.lanepe.2023.100617. eCollection 2023 Jun. Lancet Reg Health Eur. 2023. PMID: 37265783 Free PMC article.
Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study.
Falkentoft AC, Andersen J, Malik ME, Selmer C, Gæde PH, Staehr PB, Hlatky MA, Fosbøl E, Køber L, Torp-Pedersen C, Gislason GH, Gerds TA, Schou M, Bruun NE, Ruwald AC. Falkentoft AC, et al. Among authors: malik me. Lancet Reg Health Eur. 2022 Jan 25;14:100308. doi: 10.1016/j.lanepe.2022.100308. eCollection 2022 Mar. Lancet Reg Health Eur. 2022. PMID: 35146474 Free PMC article.
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE, Schou M. Jensen J, et al. Among authors: malik me. Lancet Diabetes Endocrinol. 2021 Feb;9(2):106-116. doi: 10.1016/S2213-8587(20)30382-X. Epub 2020 Dec 22. Lancet Diabetes Endocrinol. 2021. PMID: 33357505 Clinical Trial.
Age-specific mortality trends in heart failure over 25 years: a retrospective Danish nationwide cohort study.
Garred CH, Malmborg M, Malik ME, Zahir D, Christensen DM, Arulmurugananthavadivel A, Fosbøl EL, Gislason G, McMurray JJV, Petrie MC, Andersson C, Køber L, Schou M. Garred CH, et al. Among authors: malik me. Lancet Healthy Longev. 2024 May;5(5):e326-e335. doi: 10.1016/S2666-7568(24)00029-1. Lancet Healthy Longev. 2024. PMID: 38705151 Free article.
12 results